SEP 4, 2026 · JOURNAL ARTICLE
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
Allergy
Phase II single-blind RCT showing statistically significant improvement in combined symptom-medication score at 80 μg dose with robust immunological response, but limited by single-blind design, modest effect size, and need for Phase III confirmation.
Reported
Primary endpoint: CSMS reduction…24.13%
CSMS reduction (40 μg vs placebo)17.41%
Bet v 1-specific IgG increase (80…median 20-fold